Massive bee swarm sends three people to hospital in critical condition, 24 injured
A swarm of bees left 24 people injured in an unusual attack on Sunday, The Associated Press (AP) reported.
Those walking through Aurillac, a quaint French community, were stung over a 30-minute period, with three people in critical condition evacuated to a hospital.
Some 26,000 people were living in the alp town in 2022, according to the French National Institute of Statistics and Economic Studies. Aurillack is located in the Auvergne-Rhône-Alpes region of France.
Pierre Mathonier, mayor of Aurillac, told a local broadcaster that those who were left in critical condition are improving, AP reported.
One victim was a 78-year-old who suffered cardiorespiratory arrest and had to be resuscitated.
That individual is now in stable condition, while the other two are said to be in "good health," per the mayor.
Mathonier added the attack could have been related to the bees becoming more aggressive over the years.
Over a decade ago, Asian hornets were harassing a beehive that was on the roof terrace of a downtown hotel, he told AP.
Lt. Col. Michel Cayla, who runs the local fire services, said the attack was "impressive" and he has never seen an attack of this scale.
Cayla told French broadcaster TF1, "In terms of the number of victims, the panic among the people and the severity of some of the injuries, it was impressive," as AP reported.
Bee sting symptoms are mostly "minor." Victims can experience instant, sharp, burning pain, as well as a welt and swelling, according to the Mayo Clinic.
The CDC predicted an annual average of 62 deaths due to bee and hornet stings between 2000-2017 in the United States.
The beehive has been removed and relocated outside the town, according to AP.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Study Names 1 Drink That Could Help Slow Down Aging
Coffee addicts may feel vindicated after seeing the results of a recent study. A good number of people are unable to start their day properly without a nice, warm cup of joe. The caffeinated beverage often delivers the energizing jolt that many need to wake up in the morning. But coffee also comes with more long-lasting benefits, according to a recent study published in the European Journal of Nutrition. The research showed that consistent coffee consumption by those in midlife may slow down physical frailty that usually comes with old age. The study conducted in Amsterdam analyzed the coffee-drinking habits of people aged 40 to 65, the age range for those in midlife. It measured frailty by assessing five components: weight loss, weakness, exhaustion, slow gait speed and low physical activity It determined that test subjects who drank at least four cups of coffee daily fought off frailty at a better rate as they aged compared to those who didn't. While the four-cup figure seems like way too much caffeine, the study based it off a small cup size of just 4.2 fluid ounces, a much more common amount in Europe. Americans consume an average coffee cup size that's more than double that. Coffee brings with it several positive effects on the human body that help combat against frailty such as muscle mass preservation, oxidative stress reduction and support for one's metabolism. Several studies have also associated coffee consumption with a longer life span. Caffeine connoisseurs now have more reasons than ever to get the brew going early in the morning, so long as they avoid drinking their coffee on an empty Names 1 Drink That Could Help Slow Down Aging first appeared on Men's Journal on Jul 8, 2025
Yahoo
40 minutes ago
- Yahoo
Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery
LONDON, July 08, 2025--(BUSINESS WIRE)--Plexāā, a MedTech startup behind the award-winning BLOOM43 medical device for breast surgery, has announced the close of a $4.5 million funding extension round. The strategic capital infusion will support the imminent U.S. launch of BLOOM43, while also laying the groundwork for future innovations. The funding also strengthens the company's position ahead of their planned Series A fundraising round. Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 percent.1 BLOOM43 is the world's first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning™. The new technique safely and intermittently thermally preconditions the skin causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials. Along with its BLOOM43 companion app, the device has demonstrated substantial improvements in the patient experience and surgical readiness, harnessing the power of holistic Prehabilitation™ and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch. "I want to thank our team for the tremendous progress it has made to make this financing possible," said Dr. Saahil Mehta, founder and CEO of Plexāā. "Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning™, and it energizes the team as we prepare to bring BLOOM43 to a wider patient population in the U.S. and beyond. The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery." Plexāā Ltd has been backed by TCP Health Ventures (the dedicated healthcare investment arm of The Capital Partnership group of companies) who led the Seed Round. This extension round comprises existing and new investors including TCP. Further investment includes over $1.6 million in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3 million from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech. Tatum Getty, founding General Partner at THENA Capital added, "Since 2023, we've been closely tracking Plexāā's progress and the development of its first device, BLOOM43. We couldn't be more excited for Plexāā to become our first portfolio company for THENA Capital's Fund I. The company is solving a critical and under-addressed challenge across the surgical pathway- reducing post-operative complications for patients which also addresses the impact to both providers and payers. "Saahil and his team bring together clinical, engineering, and operational expertise from some of the UK's leading institutions. Their bold ambition to scale globally, beginning with an imminent commercial launch in the U.S., is exactly the kind of UK MedTech leadership team we look to champion. Our fund's commercialisation support model is well-suited to help Plexāā expand into women's health and adjacent categories where better outcomes and patient experiences are urgently needed." Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery — and to deliver transformative solutions that address unmet needs in surgical care. About Plexāā Plexāā is a pioneering UK-based MedTech company focused on improving surgical outcomes through devices and digital products. Its flagship device, BLOOM43, enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect one in three women undergoing breast surgery. Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes. About TCP Health Ventures TCP Health Ventures is the dedicated healthcare investment arm of The Capital Partnership group of companies, a multi-asset investment company with assets under management of $7 billion. Headquartered out of London, TCP Health Ventures manages assets of $ 225 million across 15+ investments in the med-tech space and has a med-tech investing experience of 10 years. About the NIHR The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low- and middle- income countries is principally funded through UK international development funding from the UK government. About THENA Capital THENA Capital is a London-based venture capital firm backing the world's next category-defining medical technologies. We invest in breakthrough companies transforming care experiences through digital health, fast-tracked medical devices, and clinical-grade innovation. THENA's debut Fund 1, focuses on high-impact, UK-founded technologies addressing unmet needs across women's health, oncology, cardiovascular disease, chronic conditions, and care delivery. With deep clinical, regulatory and operational expertise, THENA Capital partners with founders to unlock international scale, navigate complex markets, and build enduring category leaders in global healthcare. References 1 Annals of Translational Medicine, Dec 2023, Management of complications following implant-based breast reconstruction: a narrative review, Dean H. Meshkin1^, Joseph M. Firriolo1, Nolan S. Karp2, Ara A. Salibian1 View source version on Contacts Media Contacts: Sam ChoinskiPazanga Health CommunicationsSchoinski@ (860) 301-5058marketing@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 hours ago
- Associated Press
Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery
LONDON--(BUSINESS WIRE)--Jul 8, 2025-- Plexāā, a MedTech startup behind the award-winning BLOOM 43 medical device for breast surgery, has announced the close of a $4.5 million funding extension round. The strategic capital infusion will support the imminent U.S. launch of BLOOM 43, while also laying the groundwork for future innovations. The funding also strengthens the company's position ahead of their planned Series A fundraising round. Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 percent. 1 BLOOM 43 is the world's first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning ™. The new technique safely and intermittently thermally preconditions the skin causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials. Along with its BLOOM 43 companion app, the device has demonstrated substantial improvements in the patient experience and surgical readiness, harnessing the power of holistic Prehabilitation ™ and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch. 'I want to thank our team for the tremendous progress it has made to make this financing possible,' said Dr. Saahil Mehta, founder and CEO of Plexāā. 'Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning ™, and it energizes the team as we prepare to bring BLOOM 43 to a wider patient population in the U.S. and beyond. The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery.' Plexāā Ltd has been backed by TCP Health Ventures (the dedicated healthcare investment arm of The Capital Partnership group of companies) who led the Seed Round. This extension round comprises existing and new investors including TCP. Further investment includes over $1.6 million in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3 million from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech. Tatum Getty, founding General Partner at THENA Capital added, 'Since 2023, we've been closely tracking Plexāā's progress and the development of its first device, BLOOM 43. We couldn't be more excited for Plexāā to become our first portfolio company for THENA Capital's Fund I. The company is solving a critical and under-addressed challenge across the surgical pathway- reducing post-operative complications for patients which also addresses the impact to both providers and payers. 'Saahil and his team bring together clinical, engineering, and operational expertise from some of the UK's leading institutions. Their bold ambition to scale globally, beginning with an imminent commercial launch in the U.S., is exactly the kind of UK MedTech leadership team we look to champion. Our fund's commercialisation support model is well-suited to help Plexāā expand into women's health and adjacent categories where better outcomes and patient experiences are urgently needed.' Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery — and to deliver transformative solutions that address unmet needs in surgical care. About Plexāā Plexāā is a pioneering UK-based MedTech company focused on improving surgical outcomes through devices and digital products. Its flagship device, BLOOM 43, enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect one in three women undergoing breast surgery. Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes. About TCP Health Ventures TCP Health Ventures is the dedicated healthcare investment arm of The Capital Partnership group of companies, a multi-asset investment company with assets under management of $7 billion. Headquartered out of London, TCP Health Ventures manages assets of $ 225 million across 15+ investments in the med-tech space and has a med-tech investing experience of 10 years. About the NIHR The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: NIHR is funded by the Department of Health and Social Care. Its work in low- and middle- income countries is principally funded through UK international development funding from the UK government. About THENA Capital THENA Capital is a London-based venture capital firm backing the world's next category-defining medical technologies. We invest in breakthrough companies transforming care experiences through digital health, fast-tracked medical devices, and clinical-grade innovation. THENA's debut Fund 1, focuses on high-impact, UK-founded technologies addressing unmet needs across women's health, oncology, cardiovascular disease, chronic conditions, and care delivery. With deep clinical, regulatory and operational expertise, THENA Capital partners with founders to unlock international scale, navigate complex markets, and build enduring category leaders in global healthcare. References 1 Annals of Translational Medicine, Dec 2023, Management of complications following implant-based breast reconstruction: a narrative review, Dean H. Meshkin 1^, Joseph M. Firriolo 1, Nolan S. Karp 2, Ara A. Salibian 1 View source version on CONTACT: Media Contacts: Sam Choinski Pazanga Health Communications [email protected] (860) 301-5058 [email protected] KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA NEW YORK INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY HEALTH CONSUMER APPS/APPLICATIONS SURGERY PROFESSIONAL SERVICES ONCOLOGY MEDICAL DEVICES SOFTWARE DATA ANALYTICS HEALTH TECHNOLOGY WOMEN DATA MANAGEMENT SOURCE: Plexāā Copyright Business Wire 2025. PUB: 07/08/2025 03:46 PM/DISC: 07/08/2025 03:46 PM
